(0)
0 Items £0.00

Jo’s Cervical Cancer Trust responds to the announcement that bevacizumab (Avastin) for cervical cancer will be removed from the Cancer Drugs Fund

Fri, 04/09/2015 - 15:02

Sign our petition to keep bevacizumab on the CDF list 

Jo's Cervical Cancer Trust is hugely disappointed at today's announcement that bevacizumab (Avastin) for cervical cancer is to be de-listed from the Cancer Drugs Fund (CDF) from 4th November 2015.

As a result of this decision every year hundreds of women with late stage cervical cancer will be denied a drug that has shown to increase the median survival by 3.7 months with a small impact on quality of life during that period. The devastation that this is going to cause is enormous with precious time with their families and loved ones taken away from them.

We fully accept that the CDF pot isn't finite but it is confusing that this review even took place considering bevacizumab was only added to the CDF just over a year ago and scored highly.

Only topotecan with cisplatin has previously been shown to increase the survival of women with recurrent cervical cancer, and most patients in England are unable to access this combination, reviewed by NICE as they have previously received cisplatin.

Without bevacizumab, none of the chemotherapy treatments that have been shown to improve survival of patients with recurrent cervical cancer will be available to patients in England.

The removal of bevacizumab, which had just started to fulfil a large and unmet need, will result in a hugely detrimental impact on end of life for those affected by cervical cancer that could have benefitted from it.

Over the coming weeks we will be campaigning and lobbying as hard as we can to ensure this decision is turned around. For now we have launched a petition urgently calling for Pharma and NHS England to resolve this issue and come to an agreement on affordability to ensure this essential drug is continued to be made available to women living with late stage cervical cancer. Please sign it now.

For more information on bevacizumab for cervical cancer visit http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatmen...

                                - Robert Music, Chief Executive of Jo's Cervical Cancer Trust

 

For more information on the revised CDF list see: http://www.england.nhs.uk/wp-content/uploads/2015/09/ncdf-list-sept15.pdf